F8 and hemophilia A: Despite the fact that the risk of transmission of viral infections has beenconsiderably reduced thanks to drugs based on recombinant FVIII, modernsubstitution therapy with hemophilia A remains far from perfect, as it denies adecent quality of life to hemophiliacs.